Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

(RTTNews) - Japan's Astellas Pharma Inc. (ALPMY, ALPMY) announced that it has signed a definitive agreement with YASKAWA Electric Corp. to establish a joint venture for the development of a cell ...

With the power of robotics and the personalized medicine expertise of one of Japan's top drugmakers, Astellas Pharma and Yaskawa Electric Corporation are setting off on a joint venture to help stre | ...

This collaboration comes on the heels of Astellas Pharma's October 2023 memorandum of understanding with BioLabs Global and ...

Eurolab granted right to sell generic prostate cancer treatment at an affordable price for South African patients.

Astellas will “generally shift our resources to focus on slightly later-stage opportunities,” he explained. 2. Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma After reports ...

Astellas has become the first drugmaker to bring a claudin 18.2 (CLDN18.2) targeted therapy to regulatory approval, getting a green light in Japan for Vyloy as a treatment for stomach cancer.

Japanese Astellas Pharma has bought privately-owned biotech Quethera for $109 million, gaining access to its gene therapy focused on developing novel treatments for glaucoma and eye disorders.

It seemed like an extraordinary display of patriotism and unity: Japan’s biggest companies would come together to save their own, whether ailing carmaker Nissan Motor Co. or besieged convenience store ...

Novel Modes of Treatment and Drugs Spur the Demand in the Immuno-oncology Market: Fact Report ROCKVILLE, MD, UNITED STATES, March 13, ...

Fund is today announcing a significant milestone: the first administration of arpraziquantel to preschool-aged children in Uganda, in an implementation science setting. This new pediatric treatment ...